LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Maklady, Fathi"
  2. AU=Subramanian Anandaraja
  3. AU="Karrar, Arif"
  4. AU=Ott D J
  5. AU="Chang, Yunchao"
  6. AU="Cai, Yiyong"
  7. AU=Peise J.
  8. AU=Fanihagh Farsad
  9. AU="Scott, Renee J"
  10. AU="Schröder, Henrik"
  11. AU="Orellana, Guillermo"
  12. AU=Raff Hershel
  13. AU="Cantore, Italo"
  14. AU="Gillespie, Robert L."
  15. AU=Gravell Rachel J AU=Gravell Rachel J
  16. AU=Chung Leon C.
  17. AU="Nishida, Shuhei"
  18. AU="He, Xiaping"
  19. AU=Ellies Maik
  20. AU="Mahmood, Faiza"
  21. AU="C. Korin Bullen"
  22. AU="Heesen, M"
  23. AU="Besson, Naomi R"
  24. AU="Teh, Selina Shiqing K"
  25. AU=Hamilton P J
  26. AU=Rizo Aleksandra
  27. AU="Nicola Sunter"
  28. AU=Dalinka M K
  29. AU="Slim, Marine"
  30. AU=Colby J
  31. AU="Hadid, Abdenour"
  32. AU=Smarr Cory-Ann
  33. AU="Rende, Mario"
  34. AU="Evans, Leigh"
  35. AU=Brown Erwin
  36. AU=Hehlmann R
  37. AU="Azzopardi, Nicolas"
  38. AU="Surić-Mihić Marija"
  39. AU=Cismasiu Valeriu B
  40. AU="Töpfer, Änne"
  41. AU="Lemcke, Johannes"
  42. AU=Cousins Emily
  43. AU="Clarke Aileen"
  44. AU="Aparecido Corrêa, Nivaldo"
  45. AU="Meng-Ju Wang"
  46. AU=Verrills Paul
  47. AU="Chaudhari, Amol"
  48. AU="Planagumà, Jesús"
  49. AU="de Rezende, Grazielli Rocha"
  50. AU="Mohadeseh NEZAM"
  51. AU="Daniel Pecos-Martín"
  52. AU="Gentle, Popular"
  53. AU=Wang Jirui
  54. AU="Bielik, Martin"
  55. AU="Simon A.F. Darroch"
  56. AU="Suzuki, Kenichi G N"
  57. AU="Hu, Yizhong"
  58. AU=Sasaki Kotaro
  59. AU=Abd-Elsayed Alaa
  60. AU="Jung, Hee-Jun"
  61. AU="Struckmann, Stephan"
  62. AU=Coward Richard
  63. AU="Ghazizadeh, Shabnam"
  64. AU="Rebecca A Butcher"
  65. AU="Kimberlyn Roosa"
  66. AU=Chian Ri-Cheng
  67. AU="Alzalzalah, Sayed"
  68. AU=Kaufman Jonathan J
  69. AU="Kim, Jin K"
  70. AU="Zevakov, S A"
  71. AU="Sui Phang"
  72. AU="Kolomeichuk, Lilia V"
  73. AU="Sabuj Kanti Mistry"
  74. AU="Basurto-Lozada, Daniela"
  75. AU="Takashima, Shin-Ichiro"
  76. AU="Teresinha Leal"
  77. AU="Angélique B van 't Wout"
  78. AU="Roberts, Nicholas J"
  79. AU="Chauhan, Gaurav B"
  80. AU=Hanjaya-Putra Donny
  81. AU=Powell James
  82. AU="Russell, Todd"
  83. AU=Forth Scott
  84. AU="Kreutzer, Susanne" AU="Kreutzer, Susanne"
  85. AU="St John, Maie"
  86. AU=Gerhardy A
  87. AU="Qi, Huixin"
  88. AU="Dobosiewicz, May"
  89. AU="Srivastava, Rakesh"
  90. AU="Grevtsov K.I."

Suchergebnis

Treffer 1 - 7 von insgesamt 7

Suchoptionen

  1. Artikel ; Online: Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis on Frequency of Venous Thromboembolism.

    Kolluri, Nikhil / Elwazir, Mohamed Y / Rosenbaum, Andrew N / Maklady, Fathi A / AbouEzzeddine, Omar F / Kapa, Suraj / Blauwet, Lori A / Chareonthaitawee, Panithaya / McBane, Robert D / Bois, John P

    The American journal of cardiology

    2021  Band 149, Seite(n) 112–118

    Abstract: Sarcoidosis is a multisystem inflammatory condition with occasional cardiac involvement (CS), which may be associated with risk of venous thromboembolism (VTE). As data on VTE in CS are sparse and corticosteroid therapy has not been previously examined, ... ...

    Abstract Sarcoidosis is a multisystem inflammatory condition with occasional cardiac involvement (CS), which may be associated with risk of venous thromboembolism (VTE). As data on VTE in CS are sparse and corticosteroid therapy has not been previously examined, we aim to determine the association between CS, corticosteroid treatment for CS, and VTE. Patients referred to our institution with concern for sarcoidosis and underwent a positron emission tomography (PET) scan were retrospectively assessed. Chi-squared and multivariate regression analyses were conducted to determine the association between a diagnosis of sarcoidosis, CS, corticosteroid use, and VTE events. Six hundred and forty nine patients were split into 3 categories: 235 with no sarcoidosis (NS), 91 with extra-cardiac sarcoidosis only (ECS), and 323 with CS (isolated CS and/or CS with extra cardiac sarcoid). Thirty nine CS, 7 ECS, and 9 NS patients developed PE while 44 CS, 3 ECS, and 18 NS patients developed DVT. On multivariate regression, neither CS nor ECS was an independent risk factor for VTE (p >0.05) but corticosteroid use was independently associated with VTE (HR 3.06, p = 0.007 for PE, HR 6.21, p <0.0001 for DVT). On logistic regression analysis, corticosteroid dose was found to be independently associated with both PE (p = 0.001) and DVT (p = 0.007). Optimal threshold for defining VTE risk with corticosteroid therapy was a prednisone-equivalent dose of 17.5 mg. In conclusion, contrary to previous studies, this current study found that neither sarcoidosis nor CS is an independent risk factor for VTE. Rather, corticosteroid therapy was associated with an increased risk of VTE.
    Mesh-Begriff(e) Adrenal Cortex Hormones/therapeutic use ; Adult ; Aged ; Cardiomyopathies/diagnostic imaging ; Cardiomyopathies/drug therapy ; Cardiomyopathies/epidemiology ; Case-Control Studies ; Female ; Humans ; Male ; Middle Aged ; Positron-Emission Tomography ; Pulmonary Embolism/epidemiology ; Risk Factors ; Sarcoidosis/diagnostic imaging ; Sarcoidosis/drug therapy ; Sarcoidosis/epidemiology ; Venous Thromboembolism/epidemiology ; Venous Thrombosis/epidemiology
    Chemische Substanzen Adrenal Cortex Hormones
    Sprache Englisch
    Erscheinungsdatum 2021-03-20
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 80014-4
    ISSN 1879-1913 ; 0002-9149
    ISSN (online) 1879-1913
    ISSN 0002-9149
    DOI 10.1016/j.amjcard.2021.03.017
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ui IV Zs.73: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.

    Bilasy, Mohammed Elshawadfy M / Oraby, Mohammed A / Ismail, Hussein M / Maklady, Fathi A

    Journal of interventional cardiology

    2012  Band 25, Heft 4, Seite(n) 404–410

    Abstract: Background: Contrast-induced nephropathy (CIN) is the third most common cause of hospital acquired acute renal failure and is associated with increased morbidity and mortality. The use of theophylline for prevention of CIN has yielded conflicting ... ...

    Abstract Background: Contrast-induced nephropathy (CIN) is the third most common cause of hospital acquired acute renal failure and is associated with increased morbidity and mortality. The use of theophylline for prevention of CIN has yielded conflicting results. This study aimed at examining the effectiveness of theophylline in prevention of CIN when added to IV hydration and N-acetylcysteine (NAC).
    Methods: Patients with stable serum creatinine and at least moderate risk for CIN according to Mehran's risk score were included in this parallel group, 1:1, single-blind, randomized controlled trial. All patients received IV hydration (1 mL/kg per hour for 24 hours) and NAC (600 mg bid for 2 days). Patients were randomized to placebo (group P) or theophylline (200 mg in 100 mL 0.9% saline, as IV infusion 30 minutes before contrast medium (CM) administration; group T). Patients underwent standard coronary angiography ± angioplasty. Serum creatinine (SCr) was assessed just before and 72 hours after contrast administration and estimated glomerular filtration rate (eGFR) was calculated.
    Results: This study included 60 patients with mean SCr 1.44 ± 0.7 mg/dL and eGFR 60.2 ± 29.2 mL/min. Mean SCr among group T was 1.54 ± 0.7 mg/dL with eGFR 58.6 ± 28.6 mL/min, while group P showed mean SCr of 1.34 ± 0.7 mg/dL and eGFR of 61.8 ± 30.1 mL/min. Among group P, 6 (20%) patients developed CIN while none of the patients in group T developed CIN. In comparison to placebo, theophylline significantly decreased SCr (P = 0.0001) and increased eGFR (P = 0.001) at 72 hours. Multivariate regression analysis showed that receiving placebo instead of theophylline, anemia, congestive heart failure, chronic renal impairment, and high-contrast load are all independent predictors for deteriorating renal function after CM administration.
    Conclusion: Theophylline seems to be an effective prophylaxis against CIN for moderate- and high-risk patients undergoing coronary angiography or angioplasty. It offers additive protection when added to IV hydration and NAC.
    Mesh-Begriff(e) Acetylcysteine/administration & dosage ; Adult ; Aged ; Contrast Media/adverse effects ; Coronary Angiography ; Creatinine/blood ; Drug Therapy, Combination ; Female ; Glomerular Filtration Rate ; Humans ; Incidence ; Kidney Diseases/chemically induced ; Kidney Diseases/epidemiology ; Kidney Diseases/prevention & control ; Male ; Middle Aged ; Risk Assessment ; Single-Blind Method ; Sodium Chloride/administration & dosage ; Theophylline/administration & dosage ; Treatment Outcome ; Vasodilator Agents/administration & dosage
    Chemische Substanzen Contrast Media ; Vasodilator Agents ; Sodium Chloride (451W47IQ8X) ; Creatinine (AYI8EX34EU) ; Theophylline (C137DTR5RG) ; Acetylcysteine (WYQ7N0BPYC)
    Sprache Englisch
    Erscheinungsdatum 2012-08
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Randomized Controlled Trial
    ZDB-ID 1036325-7
    ISSN 1540-8183 ; 0896-4327
    ISSN (online) 1540-8183
    ISSN 0896-4327
    DOI 10.1111/j.1540-8183.2012.00730.x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2719: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.

    Connolly, Stuart J / Karthikeyan, Ganesan / Ntsekhe, Mpiko / Haileamlak, Abraham / El Sayed, Ahmed / El Ghamrawy, Alaa / Damasceno, Albertino / Avezum, Alvaro / Dans, Antonio M L / Gitura, Bernard / Hu, Dayi / Kamanzi, Emmanuel R / Maklady, Fathi / Fana, Golden / Gonzalez-Hermosillo, J Antonio / Musuku, John / Kazmi, Khawar / Zühlke, Liesl / Gondwe, Lillian /
    Ma, Changsheng / Paniagua, Maria / Ogah, Okechukwu S / Molefe-Baikai, Onkabetse J / Lwabi, Peter / Chillo, Pilly / Sharma, Sanjib K / Cabral, Tantchou T J / Tarhuni, Wadea M / Benz, Alexander / van Eikels, Martin / Krol, Amy / Pattath, Divya / Balasubramanian, Kumar / Rangarajan, Sumathy / Ramasundarahettige, Chinthanie / Mayosi, Bongani / Yusuf, Salim

    The New England journal of medicine

    2022  Band 387, Heft 11, Seite(n) 978–988

    Abstract: Background: Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited.: Methods: We enrolled patients with atrial fibrillation and ... ...

    Abstract Background: Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited.
    Methods: We enrolled patients with atrial fibrillation and echocardiographically documented rheumatic heart disease who had any of the following: a CHA
    Results: Of 4565 enrolled patients, 4531 were included in the final analysis. The mean age of the patients was 50.5 years, and 72.3% were women. Permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits. In the intention-to-treat analysis, 560 patients in the rivaroxaban group and 446 in the vitamin K antagonist group had a primary-outcome event. Survival curves were nonproportional. The restricted mean survival time was 1599 days in the rivaroxaban group and 1675 days in the vitamin K antagonist group (difference, -76 days; 95% confidence interval [CI], -121 to -31; P<0.001). A higher incidence of death occurred in the rivaroxaban group than in the vitamin K antagonist group (restricted mean survival time, 1608 days vs. 1680 days; difference, -72 days; 95% CI, -117 to -28). No significant between-group difference in the rate of major bleeding was noted.
    Conclusions: Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.).
    Mesh-Begriff(e) Anticoagulants/adverse effects ; Anticoagulants/therapeutic use ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/etiology ; Echocardiography ; Factor Xa Inhibitors/adverse effects ; Factor Xa Inhibitors/therapeutic use ; Female ; Hemorrhage/chemically induced ; Humans ; Male ; Middle Aged ; Rheumatic Heart Disease/complications ; Rheumatic Heart Disease/diagnosis ; Rheumatic Heart Disease/diagnostic imaging ; Rivaroxaban/adverse effects ; Rivaroxaban/therapeutic use ; Stroke/etiology ; Stroke/prevention & control ; Treatment Outcome ; Vitamin K/antagonists & inhibitors ; Warfarin/adverse effects ; Warfarin/therapeutic use
    Chemische Substanzen Anticoagulants ; Factor Xa Inhibitors ; Vitamin K (12001-79-5) ; Warfarin (5Q7ZVV76EI) ; Rivaroxaban (9NDF7JZ4M3)
    Sprache Englisch
    Erscheinungsdatum 2022-08-28
    Erscheinungsland United States
    Dokumenttyp Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa2209051
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ua VI Zs.34: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.

    Karthikeyan, Ganesan / Connolly, Stuart J / Ntsekhe, Mpiko / Benz, Alexander / Rangarajan, Sumathy / Lewis, Gayle / Yun, Yan / Sharma, Sanjib Kumar / Maklady, Fathi / Elghamrawy, Alaa Eldin / Kazmi, Khawar / Cabral, Tantchou T J / Dayi, Hu / Changsheng, Ma / Gitura, Bernard M / Avezum, Alvaro / Zuhlke, Liesl / Lwabi, Peter / Haileamlak, Abraham /
    Ogah, Okechukwu / Chillo, Pilly / Paniagua, Maria / ElSayed, Ahmed / Dans, Antonio / Gondwe-Chunda, Lillian / Molefe-Baikai, Onkabetse Julia / Gonzalez-Hermosillo, Jesus A / Hakim, James / Damasceno, Albertino / Kamanzi, Emmanuel R / Musuku, John / Davletov, Kairat / Connolly, Katherine / Mayosi, Bongani M / Yusuf, Salim

    American heart journal

    2020  Band 225, Seite(n) 69–77

    Abstract: Background: Rheumatic heart disease (RHD) is a neglected disease affecting 33 million people, mainly in low and middle income countries. Yet very few large trials or registries have been conducted in this population. The INVICTUS program of research in ... ...

    Abstract Background: Rheumatic heart disease (RHD) is a neglected disease affecting 33 million people, mainly in low and middle income countries. Yet very few large trials or registries have been conducted in this population. The INVICTUS program of research in RHD consists of a randomized-controlled trial (RCT) of 4500 patients comparing rivaroxaban with vitamin K antagonists (VKA) in patients with RHD and atrial fibrillation (AF), a registry of 17,000 patients to document the contemporary clinical course of patients with RHD, including a focused sub-study on pregnant women with RHD within the registry. This paper describes the rationale, design, organization and baseline characteristics of the RCT and a summary of the design of the registry and its sub-study. Patients with RHD and AF are considered to be at high risk of embolic strokes, and oral anticoagulation with VKAs is recommended for stroke prevention. But the quality of anticoagulation with VKA is poor in developing countries. A drug which does not require monitoring, and which is safe and effective for preventing stroke in patients with valvular AF, would fulfill a major unmet need.
    Methods: The INVestIgation of rheumatiC AF Treatment Using VKAs, rivaroxaban or aspirin Studies (INVICTUS-VKA) trial is an international, multicentre, randomized, open-label, parallel group trial, testing whether rivaroxaban 20 mg given once daily is non-inferior (or superior) to VKA in patients with RHD, AF, and an elevated risk of stroke (mitral stenosis with valve area ≤2 cm
    Conclusion: INVICTUS is the largest program of clinical research focused on a neglected cardiovascular disease and will provide new information on the clinical course of patients with RHD, and approaches to anticoagulation in those with concomitant AF.
    Mesh-Begriff(e) Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Pregnancy ; Atrial Fibrillation/complications ; Atrial Fibrillation/drug therapy ; Embolism/prevention & control ; Factor Xa Inhibitors/adverse effects ; Factor Xa Inhibitors/therapeutic use ; Hemorrhage/chemically induced ; Pregnancy Complications, Cardiovascular/drug therapy ; Rheumatic Heart Disease/complications ; Rheumatic Heart Disease/drug therapy ; Rivaroxaban/adverse effects ; Rivaroxaban/therapeutic use ; Stroke/prevention & control ; Vitamin K/antagonists & inhibitors ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic
    Chemische Substanzen Factor Xa Inhibitors ; Rivaroxaban (9NDF7JZ4M3) ; Vitamin K (12001-79-5)
    Sprache Englisch
    Erscheinungsdatum 2020-03-25
    Erscheinungsland United States
    Dokumenttyp Clinical Trial Protocol ; Journal Article
    ZDB-ID 80026-0
    ISSN 1097-6744 ; 0002-8703
    ISSN (online) 1097-6744
    ISSN 0002-8703
    DOI 10.1016/j.ahj.2020.03.018
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ui IV Zs.15: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel: Assessment of myocardial perfusion during pharmacologic contrast stress echocardiography.

    Oraby, Mohamed A / Hays, Janet / Maklady, Fathi A / El-Hawary, Ahmed A / Zabalgoitia, Miguel

    The American journal of cardiology

    2002  Band 89, Heft 5, Seite(n) 640–644

    Mesh-Begriff(e) Albumins ; Contrast Media ; Coronary Circulation/physiology ; Coronary Disease/diagnostic imaging ; Coronary Disease/physiopathology ; Dipyridamole ; Echocardiography ; Equipment Design ; Exercise Test ; Fluorocarbons ; Humans ; Myocardial Contraction/physiology ; Sensitivity and Specificity ; Thallium Radioisotopes ; Tomography, Emission-Computed, Single-Photon
    Chemische Substanzen Albumins ; Contrast Media ; FS 069 ; Fluorocarbons ; Thallium Radioisotopes ; Dipyridamole (64ALC7F90C)
    Sprache Englisch
    Erscheinungsdatum 2002-03-01
    Erscheinungsland United States
    Dokumenttyp Comparative Study ; Evaluation Studies ; Journal Article
    ZDB-ID 80014-4
    ISSN 1879-1913 ; 0002-9149
    ISSN (online) 1879-1913
    ISSN 0002-9149
    DOI 10.1016/s0002-9149(01)02317-7
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ui IV Zs.73: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel: Impact of bifurcation lesions on clinical outcome and prognosis of primary angioplasty in acute myocardial infarction.

    Abdel-Hakim, Diaa-Eldin / Garot, Philippe / Champagne, Stéphane / Maklady, Fathi / el-Hawary, Ahmed / Dubois-Randé, Jean-Luc / Lesault, Pierre-François / Teiger, Emmanuel

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

    2008  Band 4, Heft 1, Seite(n) 93–98

    Abstract: Aims: The aim of this study was to determine the impact of bifurcation lesions on outcomes after primary percutaneous intervention (PCI) for acute myocardial infarction.: Methods and results: We retrospectively reviewed a single-centre database of ... ...

    Abstract Aims: The aim of this study was to determine the impact of bifurcation lesions on outcomes after primary percutaneous intervention (PCI) for acute myocardial infarction.
    Methods and results: We retrospectively reviewed a single-centre database of 646 patients admitted for primary angioplasty within 12 hours after AMI. We compared baseline characteristics and outcomes between bifurcation and non-bifurcation lesions. Bifurcation lesions were found in 23% of patients. They predominantly involved the left anterior descending artery. Provisional T-stenting was used in 89.3% of patients (with stenting of the main branch in 82% and of both branches in 7.3%), side-branch protection in 54.6%, and final kissing balloon inflation in 33%. The procedural success rate was 92% for the main branch of bifurcation lesions compared with 93% for non-bifurcation lesions (P=0.65). Major adverse cardiac event (MACE) rates were comparable in the two groups: in-hospital MACE was 13.3% in the bifurcation group versus 11.4% in the non-bifurcation group (P=0.72), and the 1-year total MACE rate was 22.6% in the bifurcation group versus 19.5% in the non-bifurcation group (P=0.56).
    Conclusions: Bifurcation lesions are common in patients with AMI. In a population with AMI, immediate and mid-term outcomes of primary PCI were similar in patients with and without bifurcation lesions.
    Mesh-Begriff(e) Aged ; Angioplasty, Balloon, Coronary ; Coronary Angiography ; Coronary Artery Disease/diagnostic imaging ; Coronary Artery Disease/pathology ; Coronary Artery Disease/therapy ; Coronary Vessels/pathology ; Databases, Factual ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Myocardial Infarction/diagnostic imaging ; Myocardial Infarction/pathology ; Myocardial Infarction/therapy ; Prognosis ; Retrospective Studies ; Treatment Outcome
    Sprache Englisch
    Erscheinungsdatum 2008-12-25
    Erscheinungsland France
    Dokumenttyp Journal Article
    ZDB-ID 2457174-X
    ISSN 1969-6213 ; 1774-024X
    ISSN (online) 1969-6213
    ISSN 1774-024X
    DOI 10.4244/eijv4i1a16
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6680: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 571: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel: Comparison of real-time coherent contrast imaging to dipyridamole thallium-201 single-photon emission computed tomography for assessment of myocardial perfusion and left ventricular wall motion.

    Oraby, Mohamed A / Hays, Janet / Maklady, Fathi A / El-Hawary, Ahmed A / Yaneza, Liberty O / Zabalgoitia, Miguel

    The American journal of cardiology

    2002  Band 90, Heft 5, Seite(n) 449–454

    Abstract: Real-time coherent contrast imaging (CCI) echocardiography has the ability to evaluate wall motion and myocardial perfusion simultaneously, but its clinical applicability in the diagnosis of coronary artery disease (CAD) remains to be determined. This ... ...

    Abstract Real-time coherent contrast imaging (CCI) echocardiography has the ability to evaluate wall motion and myocardial perfusion simultaneously, but its clinical applicability in the diagnosis of coronary artery disease (CAD) remains to be determined. This study examines the level of agreement between real-time CCI echocardiography and thallium-201 single-photon emission computed tomography (SPECT) following stress vasodilation. Forty-two patients with known or suspected CAD underwent real-time CCI using octafluoropropane-filled microspheres infusion before and after dipyridamole and thallium-201 injections. The apical 4- and 2-chamber views were each divided into 6 segments to assess wall motion and perfusion. Real-time CCI and SPECT were interpreted independently. Thirty-eight patients successfully completed tests, and 4 had suboptimal contrast images. Each vascular territory was classified as normal or abnormal by CCI perfusion, wall motion, and SPECT at baseline and at stress. Of the 114 territories (3 in each of the 38 patients), 3 (3.5%) were not analyzed; however, all territories corresponding to the left anterior descending artery were suitable for analysis. Concordance between CCI echocardiography and thallium-201 SPECT perfusion for left anterior descending, left circumflex, and right coronary artery territories were 91%, 86%, and 69%, respectively; between CCI perfusion and wall motion, the correlations were 93%, 93%, and 91%, respectively. When CCI perfusion and wall motion analysis were combined, their concordance to thallium-201 SPECT uptake improved to 94%, 89%, and 79%, respectively. In conclusion, real-time CCI echocardiography agrees very closely with thallium-201 SPECT in assessing myocardial perfusion following vasodilatory stress. Assessment of myocardial perfusion, in addition to segmental wall motion analysis, during stress echocardiography may be a significant contribution to the noninvasive evaluation of patients with ischemic heart disease.
    Mesh-Begriff(e) Aged ; Aged, 80 and over ; Arteries/diagnostic imaging ; Cohort Studies ; Contrast Media ; Coronary Vessels/diagnostic imaging ; Dipyridamole ; Echocardiography ; Heart Ventricles/diagnostic imaging ; Humans ; Male ; Middle Aged ; Myocardial Ischemia/diagnosis ; Myocardial Ischemia/physiopathology ; Myocardium/pathology ; Perfusion ; Radiopharmaceuticals ; Thallium Radioisotopes ; Tomography, Emission-Computed, Single-Photon ; Vasodilator Agents ; Ventricular Function
    Chemische Substanzen Contrast Media ; Radiopharmaceuticals ; Thallium Radioisotopes ; Vasodilator Agents ; Dipyridamole (64ALC7F90C)
    Sprache Englisch
    Erscheinungsdatum 2002-09-01
    Erscheinungsland United States
    Dokumenttyp Comparative Study ; Evaluation Studies ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80014-4
    ISSN 1879-1913 ; 0002-9149
    ISSN (online) 1879-1913
    ISSN 0002-9149
    DOI 10.1016/s0002-9149(02)02512-2
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ui IV Zs.73: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang